Trial Profile
A Two-Part Phase 1 Healthy Volunteer Study: A Crossover Comparison of CTP-656 Solid Dose Formulation vs. Kalydeco and a Double-Blind, Placebo-Controlled, Ascending Multiple Dose Evaluation of CTP-656
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs Deutivacaftor (Primary) ; Ivacaftor
- Indications Cystic fibrosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Concert Pharmaceuticals
- 21 Sep 2016 According to a Concert Pharmaceuticals media release, results from this study will be presented at the 30th Annual North American Cystic Fibrosis Conference.
- 10 Jun 2016 Results from this trial were presented at the European Cystic Fibrosis Conference, according to a Concert Pharmaceuticals media release.
- 10 Jun 2016 Results published in a Concert Pharmaceuticals media release.